Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study.

Abstract

OBJECTIVE To address the ability of a 24-week Maraviroc (MVC) intensification of a stable antiretroviral therapy (cART) to significantly increase the CD4 cell count slope. METHODS Patients were eligible if they had CD4 <350 cells/mm, a CD4 slope <50 cells/mm per year, and sustained plasma HIV-RNA <50 copies/mL over the last 2 years, while receiving a… (More)
DOI: 10.1097/QAI.0b013e318273015f

Topics

Cite this paper

@article{Cuzin2012MaravirocIO, title={Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study.}, author={Lise Cuzin and Selma Trabelsi and Pierre Delobel and Claudine Barbuat and J. P. Reynes and Clotilde Allavena and Gilles Peytavin and Jade Ghosn and Caroline Lascoux-Combe and Christina K Psomas and Pierre Corbeau and Philippe Flandre}, journal={Journal of acquired immune deficiency syndromes}, year={2012}, volume={61 5}, pages={557-64} }